All In Biotech

Drug Trial Radar · NCT03216564

An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes

Intervention Using Vitamin D for Elevated Urinary ALbumin in Diabetes (IDEAL-2)

Last checked: Nov 20, 2026Latest source record: Sep 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

320

Planned (sponsor's estimate)

Start

May 10, 2017

Primary completion

May 10, 2019

Study completion May 10, 2019

Sponsor

Lead sponsor
Hamad Medical CorporationIndustry
Sponsor type
Industry
Collaborators
Weill Cornell Medical College in Qatar
First posted
Jul 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Diabetic kidney disease (nephropathy) develops in nearly 40% of patients with type 2 diabetes mellitus. Diabetic nephropathy is caused by damage to the small blood vessels in the kidneys due to uncontrolled blood sugar levels, which mean that the kidneys become less effective at filtering urine. This is associated with albuminuria (protein in the urine). Treatment with some drugs reduces the loss of albumin through the urine and delays disease progression. There is increasing evidence that vitamin D could also be important in management of diabetic kidney disease. The aim of this study is to investigate the efficacy and safety of a combined regimen of calcitriol (active vitamin D) and established drugs for diabetic kidney disease.

Conditions

  • Diabetic Nephropathies

Interventions

  • CalcitriolDrug

    Active vitamin D (Calcitriol) 0.25 micrograms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinary albumin creatinine ratio (ACR) measured biochemicallyTime frame: 26 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hamad Medical Corporation

    Doha, Qatar · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.